Intrinsic value of BeiGene ADR - BGNE

Previous Close

$124.23

  Intrinsic Value

$3.02

stock screener

  Rating & Target

str. sell

-98%

Previous close

$124.23

 
Intrinsic value

$3.02

 
Up/down potential

-98%

 
Rating

str. sell

We calculate the intrinsic value of BGNE stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 6.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  243
  249
  255
  262
  270
  279
  288
  299
  310
  322
  334
  348
  363
  378
  394
  411
  430
  449
  469
  491
  514
  538
  563
  590
  618
  647
  679
  711
  746
  782
Variable operating expenses, $m
  5,369
  5,492
  5,633
  5,792
  5,967
  6,160
  6,370
  6,597
  6,841
  7,104
  7,382
  7,682
  8,001
  8,340
  8,700
  9,081
  9,485
  9,912
  10,362
  10,839
  11,341
  11,871
  12,429
  13,018
  13,637
  14,290
  14,977
  15,699
  16,460
  17,260
Fixed operating expenses, $m
  98
  100
  102
  105
  107
  109
  112
  114
  117
  119
  122
  125
  127
  130
  133
  136
  139
  142
  145
  148
  152
  155
  158
  162
  165
  169
  173
  177
  180
  184
Total operating expenses, $m
  5,467
  5,592
  5,735
  5,897
  6,074
  6,269
  6,482
  6,711
  6,958
  7,223
  7,504
  7,807
  8,128
  8,470
  8,833
  9,217
  9,624
  10,054
  10,507
  10,987
  11,493
  12,026
  12,587
  13,180
  13,802
  14,459
  15,150
  15,876
  16,640
  17,444
Operating income, $m
  -5,224
  -5,344
  -5,481
  -5,634
  -5,804
  -5,990
  -6,193
  -6,412
  -6,648
  -6,901
  -7,170
  -7,459
  -7,766
  -8,092
  -8,439
  -8,806
  -9,194
  -9,605
  -10,038
  -10,496
  -10,979
  -11,488
  -12,025
  -12,590
  -13,185
  -13,812
  -14,471
  -15,165
  -15,895
  -16,662
EBITDA, $m
  -5,217
  -5,337
  -5,474
  -5,627
  -5,797
  -5,983
  -6,186
  -6,405
  -6,640
  -6,893
  -7,164
  -7,452
  -7,759
  -8,086
  -8,432
  -8,798
  -9,186
  -9,596
  -10,030
  -10,487
  -10,969
  -11,478
  -12,014
  -12,579
  -13,174
  -13,800
  -14,459
  -15,152
  -15,881
  -16,648
Interest expense (income), $m
  1
  9
  6
  7
  7
  8
  8
  9
  10
  10
  11
  12
  13
  14
  15
  16
  17
  18
  20
  21
  23
  24
  26
  27
  29
  31
  33
  35
  37
  40
  42
Earnings before tax, $m
  -5,233
  -5,350
  -5,487
  -5,641
  -5,812
  -5,999
  -6,202
  -6,422
  -6,658
  -6,912
  -7,182
  -7,472
  -7,780
  -8,107
  -8,455
  -8,823
  -9,212
  -9,624
  -10,059
  -10,518
  -11,003
  -11,514
  -12,052
  -12,619
  -13,216
  -13,845
  -14,506
  -15,202
  -15,934
  -16,704
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -5,233
  -5,350
  -5,487
  -5,641
  -5,812
  -5,999
  -6,202
  -6,422
  -6,658
  -6,912
  -7,182
  -7,472
  -7,780
  -8,107
  -8,455
  -8,823
  -9,212
  -9,624
  -10,059
  -10,518
  -11,003
  -11,514
  -12,052
  -12,619
  -13,216
  -13,845
  -14,506
  -15,202
  -15,934
  -16,704

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  357
  365
  375
  385
  397
  410
  424
  439
  455
  472
  491
  511
  532
  555
  579
  604
  631
  659
  689
  721
  755
  790
  827
  866
  907
  951
  996
  1,044
  1,095
  1,148
Adjusted assets (=assets-cash), $m
  357
  365
  375
  385
  397
  410
  424
  439
  455
  472
  491
  511
  532
  555
  579
  604
  631
  659
  689
  721
  755
  790
  827
  866
  907
  951
  996
  1,044
  1,095
  1,148
Revenue / Adjusted assets
  0.681
  0.682
  0.680
  0.681
  0.680
  0.680
  0.679
  0.681
  0.681
  0.682
  0.680
  0.681
  0.682
  0.681
  0.680
  0.680
  0.681
  0.681
  0.681
  0.681
  0.681
  0.681
  0.681
  0.681
  0.681
  0.680
  0.682
  0.681
  0.681
  0.681
Average production assets, $m
  50
  51
  53
  54
  56
  58
  60
  62
  64
  67
  69
  72
  75
  78
  82
  85
  89
  93
  97
  102
  106
  111
  117
  122
  128
  134
  140
  147
  154
  162
Working capital, $m
  -66
  -68
  -69
  -71
  -74
  -76
  -78
  -81
  -84
  -88
  -91
  -95
  -99
  -103
  -107
  -112
  -117
  -122
  -128
  -134
  -140
  -146
  -153
  -160
  -168
  -176
  -185
  -193
  -203
  -213
Total debt, $m
  119
  126
  134
  144
  154
  166
  179
  192
  207
  222
  239
  257
  276
  297
  318
  341
  365
  391
  418
  446
  476
  508
  541
  577
  614
  653
  694
  737
  783
  831
Total liabilities, $m
  321
  329
  337
  347
  357
  369
  381
  395
  410
  425
  442
  460
  479
  499
  521
  544
  568
  593
  620
  649
  679
  711
  744
  779
  817
  856
  897
  940
  986
  1,033
Total equity, $m
  36
  37
  37
  39
  40
  41
  42
  44
  46
  47
  49
  51
  53
  55
  58
  60
  63
  66
  69
  72
  75
  79
  83
  87
  91
  95
  100
  104
  110
  115
Total liabilities and equity, $m
  357
  366
  374
  386
  397
  410
  423
  439
  456
  472
  491
  511
  532
  554
  579
  604
  631
  659
  689
  721
  754
  790
  827
  866
  908
  951
  997
  1,044
  1,096
  1,148
Debt-to-equity ratio
  3.320
  3.450
  3.590
  3.740
  3.890
  4.050
  4.210
  4.380
  4.540
  4.710
  4.870
  5.030
  5.190
  5.350
  5.500
  5.640
  5.790
  5.930
  6.060
  6.190
  6.310
  6.430
  6.550
  6.660
  6.770
  6.870
  6.970
  7.060
  7.150
  7.230
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -5,233
  -5,350
  -5,487
  -5,641
  -5,812
  -5,999
  -6,202
  -6,422
  -6,658
  -6,912
  -7,182
  -7,472
  -7,780
  -8,107
  -8,455
  -8,823
  -9,212
  -9,624
  -10,059
  -10,518
  -11,003
  -11,514
  -12,052
  -12,619
  -13,216
  -13,845
  -14,506
  -15,202
  -15,934
  -16,704
Depreciation, amort., depletion, $m
  6
  6
  7
  7
  7
  7
  7
  7
  8
  8
  6
  6
  7
  7
  7
  7
  8
  8
  9
  9
  9
  10
  10
  11
  11
  12
  12
  13
  14
  14
Funds from operations, $m
  -5,226
  -5,344
  -5,481
  -5,635
  -5,805
  -5,992
  -6,195
  -6,414
  -6,651
  -6,905
  -7,176
  -7,465
  -7,773
  -8,101
  -8,448
  -8,815
  -9,205
  -9,616
  -10,051
  -10,510
  -10,994
  -11,504
  -12,042
  -12,608
  -13,205
  -13,833
  -14,494
  -15,189
  -15,921
  -16,690
Change in working capital, $m
  -1
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -6
  -7
  -7
  -7
  -8
  -8
  -8
  -9
  -9
  -10
Cash from operations, $m
  -5,225
  -5,342
  -5,479
  -5,633
  -5,803
  -5,989
  -6,192
  -6,412
  -6,648
  -6,901
  -7,172
  -7,462
  -7,769
  -8,096
  -8,443
  -8,811
  -9,200
  -9,611
  -10,045
  -10,504
  -10,987
  -11,497
  -12,035
  -12,601
  -13,197
  -13,825
  -14,485
  -15,180
  -15,911
  -16,680
Maintenance CAPEX, $m
  -4
  -4
  -5
  -5
  -5
  -5
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -7
  -7
  -8
  -8
  -9
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -12
  -13
  -14
New CAPEX, $m
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -5
  -5
  -5
  -6
  -6
  -6
  -6
  -7
  -7
  -8
Cash from investing activities, $m
  -5
  -5
  -6
  -6
  -7
  -7
  -7
  -7
  -7
  -8
  -9
  -9
  -9
  -10
  -10
  -11
  -11
  -12
  -12
  -13
  -14
  -14
  -15
  -16
  -17
  -17
  -18
  -19
  -20
  -22
Free cash flow, $m
  -5,230
  -5,348
  -5,485
  -5,639
  -5,809
  -5,996
  -6,199
  -6,419
  -6,656
  -6,909
  -7,181
  -7,470
  -7,779
  -8,106
  -8,453
  -8,821
  -9,211
  -9,623
  -10,058
  -10,517
  -11,001
  -11,512
  -12,050
  -12,617
  -13,214
  -13,842
  -14,504
  -15,199
  -15,931
  -16,701
Issuance/(repayment) of debt, $m
  -46
  7
  8
  9
  11
  12
  13
  14
  15
  16
  17
  18
  19
  20
  22
  23
  24
  26
  27
  29
  30
  32
  33
  35
  37
  39
  41
  43
  46
  48
Issuance/(repurchase) of shares, $m
  5,286
  5,351
  5,488
  5,642
  5,813
  6,000
  6,203
  6,423
  6,660
  6,914
  7,184
  7,474
  7,782
  8,110
  8,457
  8,825
  9,215
  9,627
  10,062
  10,522
  11,006
  11,517
  12,056
  12,623
  13,220
  13,849
  14,511
  15,207
  15,939
  16,710
Cash from financing (excl. dividends), $m  
  5,240
  5,358
  5,496
  5,651
  5,824
  6,012
  6,216
  6,437
  6,675
  6,930
  7,201
  7,492
  7,801
  8,130
  8,479
  8,848
  9,239
  9,653
  10,089
  10,551
  11,036
  11,549
  12,089
  12,658
  13,257
  13,888
  14,552
  15,250
  15,985
  16,758
Total cash flow (excl. dividends), $m
  9
  11
  12
  13
  14
  16
  17
  18
  19
  20
  20
  21
  22
  24
  25
  27
  28
  30
  32
  33
  35
  37
  39
  41
  44
  46
  48
  51
  53
  56
Retained Cash Flow (-), $m
  -5,286
  -5,351
  -5,488
  -5,642
  -5,813
  -6,000
  -6,203
  -6,423
  -6,660
  -6,914
  -7,184
  -7,474
  -7,782
  -8,110
  -8,457
  -8,825
  -9,215
  -9,627
  -10,062
  -10,522
  -11,006
  -11,517
  -12,056
  -12,623
  -13,220
  -13,849
  -14,511
  -15,207
  -15,939
  -16,710
Prev. year cash balance distribution, $m
  688
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -4,589
  -5,340
  -5,477
  -5,629
  -5,799
  -5,984
  -6,187
  -6,405
  -6,641
  -6,894
  -7,164
  -7,453
  -7,760
  -8,086
  -8,432
  -8,799
  -9,187
  -9,597
  -10,031
  -10,488
  -10,971
  -11,480
  -12,016
  -12,582
  -13,177
  -13,803
  -14,463
  -15,156
  -15,886
  -16,653
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -4,400
  -4,889
  -4,766
  -4,635
  -4,495
  -4,343
  -4,180
  -4,003
  -3,815
  -3,614
  -3,402
  -3,180
  -2,950
  -2,715
  -2,475
  -2,236
  -1,999
  -1,767
  -1,544
  -1,333
  -1,135
  -953
  -788
  -641
  -513
  -403
  -310
  -234
  -173
  -125
Current shareholders' claim on cash, %
  50.0
  3.1
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

FINANCIAL RATIOS  of  BeiGene ADR (BGNE)

Valuation Ratios
P/E Ratio -538.5
Price to Sales 64081.6
Price to Book 181.5
Price to Tangible Book
Price to Cash Flow -712
Price to Free Cash Flow -562.1
Growth Rates
Sales Growth Rate -88.9%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 380%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 4.8%
Total Debt to Equity 4.8%
Interest Coverage -118
Management Effectiveness
Return On Assets -45.1%
Ret/ On Assets - 3 Yr. Avg. -55.4%
Return On Total Capital -51.2%
Ret/ On T. Cap. - 3 Yr. Avg. -88.1%
Return On Equity -55.7%
Return On Equity - 3 Yr. Avg. 35.7%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -11600%
EBITDA Margin - 3 Yr. Avg. -4114%
Operating Margin -11700%
Oper. Margin - 3 Yr. Avg. -4144.4%
Pre-Tax Margin -11900%
Pre-Tax Margin - 3 Yr. Avg. -4226.5%
Net Profit Margin -11900%
Net Profit Margin - 3 Yr. Avg. -4223.9%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

BGNE stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the BGNE stock intrinsic value calculation we used $238.387 million for the last fiscal year's total revenue generated by BeiGene ADR. The default revenue input number comes from 0001 income statement of BeiGene ADR. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our BGNE stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for BGNE is calculated based on our internal credit rating of BeiGene ADR, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of BeiGene ADR.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of BGNE stock the variable cost ratio is equal to 2208%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $96 million in the base year in the intrinsic value calculation for BGNE stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for BeiGene ADR.

Corporate tax rate of 27% is the nominal tax rate for BeiGene ADR. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the BGNE stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for BGNE are equal to 20.7%.

Life of production assets of 11.4 years is the average useful life of capital assets used in BeiGene ADR operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for BGNE is equal to -27.2%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $669.809 million for BeiGene ADR - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 53.765 million for BeiGene ADR is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of BeiGene ADR at the current share price and the inputted number of shares is $6.7 billion.

RELATED COMPANIES Price Int.Val. Rating
MRK Merck&Co 74.09 33.05  str.sell
ARRY Array BioPharm 14.53 0.01  str.sell
TSRO TESARO 25.99 0.88  str.sell
AZN AstraZeneca AD 41.40 162.71  str.buy
CLVS Clovis Oncolog 15.08 1.35  str.sell
CELG Celgene 69.63 340.31  str.buy

COMPANY NEWS

▶ Chinas Innovent Extends Gain from Solid HK IPO   [Nov-02-18 04:11AM  Investing.com]
▶ 3 Biotechs Poised for 10% Gains   [Sep-27-18 06:00AM  Investopedia]
▶ BeiGene to Present at Upcoming Investor Conferences   [Sep-25-18 06:00AM  GlobeNewswire]
▶ [$$] SpringWorks Joins BeiGene in Cancer Drug Collaboration   [Sep-06-18 06:56PM  The Wall Street Journal]
▶ 3 Biotech Stocks That May Rise as Much as 16%   [Aug-24-18 02:00PM  Investopedia]
▶ China Tower, BeiGene Make Trading Debut in Hong Kong   [Aug-07-18 11:32PM  Bloomberg Video]
▶ Here's Why BeiGene Rose 23.4% in July   [Aug-04-18 06:03PM  Motley Fool]
▶ [$$] Chinese Cancer-Drugmaker Raises $900 Million in Hong Kong Listing   [Aug-02-18 07:39AM  The Wall Street Journal]
▶ 3 Reasons BeiGene Needs to Be on Your Radar   [Jul-03-18 10:45PM  Motley Fool]
▶ These Stocks Have Quadrupled in Just 1 Year   [May-19-18 11:49AM  Motley Fool]
▶ BeiGene Reports First Quarter 2018 Financial Results   [May-09-18 04:15PM  GlobeNewswire]
▶ BeiGene Appoints J. Samuel Su to its Board of Directors   [Apr-03-18 07:00AM  GlobeNewswire]
▶ BeiGene to Present at Upcoming Investor Conferences   [Mar-05-18 07:00AM  GlobeNewswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.